FDA Approves Durvalumab with BCG for Bladder Cancer
FDA Approves Durvalumab in Combination with BCG for High-Risk Non-Muscle Invasive Bladder Cancer
The U.S. Food and Drug Administration (FDA) has approved durvalumab (Imfinzi) in combination with Bacillus Calmette-Guerin (BCG) for the treatment of high-risk non-muscle invasive bladder cancer (NMIBC). This approval provides a new option for patients who do not respond to standard therapy.
Clinical Trial Results
The approval is based on a phase 3 trial showing that the combination of durvalumab and BCG improved outcomes compared to BCG alone or BCG with another immunotherapy. Patients receiving the combination had a significantly higher tumor-free survival rate.
Safety Profile
Common side effects included fatigue, urinary tract infection, and musculoskeletal pain. Immune-related adverse events occurred at a similar rate to durvalumab monotherapy.
This approval represents a significant advance in bladder cancer treatment, offering patients a more effective therapeutic option.
Impacted Symbols
Symbols affected by this headline and their sentiment signals
The news, analyses, and comments on this platform do not constitute investment advice. When making investment decisions, you should conduct your own research and consult with a qualified financial advisor if necessary. FiNews cannot be held responsible for any losses that may arise from the use of this information.
More Headlines
Tokyo Core Inflation Slows, Remains Below BOJ Target
Tokyo Core Inflation Slows, Remains Below BOJ Target
…Nikkei May Rise on Hopes for U.S.-Iran Peace Deal
Nikkei May Rise on Hopes for U.S.-Iran Peace Deal
…Australian Pension Fund HUB24 Faces Regulatory Scrutiny
Australian Pension Fund HUB24 Faces Regulatory Scrutiny
…